CSL Limited Sponsored ADR (OTCMKTS:CSLLY) Sees Significant Decline in Short Interest

CSL Limited Sponsored ADR (OTCMKTS:CSLLY) was the target of a significant decrease in short interest in the month of July. As of July 31st, there was short interest totaling 326,576 shares, a decrease of 37.2% from the July 15th total of 519,924 shares. Currently, 0.0% of the company’s stock are sold short. Based on an average daily volume of 497,187 shares, the days-to-cover ratio is presently 0.7 days.

CSL Stock Down 0.7%

CSLLY opened at $23.95 on Tuesday. The business has a 50 day moving average price of $21.12 and a two-hundred day moving average price of $27.51. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.15 and a current ratio of 2.57. CSL has a 1-year low of $16.01 and a 1-year high of $44.77.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Citigroup downgraded CSL from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 11th. Canaccord Genuity Group downgraded CSL from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 11th. Zacks Research upgraded CSL from a “strong sell” rating to a “hold” rating in a research report on Friday, August 7th. Finally, Jefferies Financial Group cut CSL from a “strong-buy” rating to a “hold” rating in a research note on Friday, May 29th. Five research analysts have rated the stock with a Hold rating, According to data from MarketBeat, the company has a consensus rating of “Hold”.

About CSL

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.